India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
Novo Nordisk A/S (NYSE:NVO): A Strong Pipeline to Aid Recovery
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...
Novo Nordisk downgraded to Hold from Buy at Stifel
Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...
Novo Nordisk added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent ...
Pharmaceutical Technology16m
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...
Eucalyptus says weight loss drugs sales are booming
A steady supply of weight-loss drugs Wegovy and Mounjaro has helped lift Eucalyptus’ revenue from $78 million to $121 million ...
Biocomposites; Novo Holdings; TA Associates: Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth
Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...